ABVC BioPharma Determined That It Has A Material Weakness In Its Internal Controls Over Financial Reporting; Concluded That Financial Statements For FY Ended Dec 31, 2023 Should No Longer Be Relied Upon Due To Errors In Financial Statements

Benzinga · 04/15 20:43

- SEC Filing